THE WOODLANDS, Texas, August 12, 2026
Autonomix Medical, Inc. announced the successful completion of a Good Laboratory Practice (GLP) preclinical study, marking an important regulatory milestone as the company prepares for a planned U.S. Food and Drug Administration (FDA) submission for its investigational medical device platform. Conducted in accordance with FDA GLP standards, the study evaluated the safety, functionality and performance of the Autonomix platform across multiple clinically relevant anatomical targets in porcine models. Final histopathology and laboratory analyses supported the safety and performance objectives previously reported by the company. The completed study is expected to provide important data for Autonomix’s regulatory package as it advances its proprietary precision nerve-targeted technology toward clinical-stage development. The company said the findings reinforce its development roadmap and provide additional validation as it moves closer to FDA regulatory engagement.
GLP Study Supports Safety and Device Performance
The completed GLP preclinical program was designed to evaluate system performance and procedural feasibility across multiple target anatomies while generating safety data relevant to future regulatory submissions. The study included comprehensive post-procedure histopathological evaluations and laboratory assessments designed to characterize tissue effects and evaluate the overall safety profile of the technology. According to Autonomix, the final laboratory and pathology findings were consistent with the positive safety and performance outcomes observed during the study. The company expects the resulting data to form an important component of its planned FDA submission, although completion of a GLP study does not itself mean that the device has received FDA clearance or approval. Additional regulatory review and requirements will determine the next steps for the investigational platform. Autonomix described the milestone as an important transition from preclinical development toward a more advanced stage of regulatory and clinical execution.
Autonomix Advances Precision Nerve-Targeted Technology
Autonomix’s proprietary platform is built around a catheter-based microchip sensing array designed to detect and differentiate neural signals with potentially greater sensitivity than existing technologies. The company is developing the system with the goal of enabling transvascular diagnosis and treatment of peripheral nervous system diseases across different anatomical locations. The initial development focus is on pain, including applications involving pancreatic cancer, where severe and difficult-to-manage pain remains a significant clinical challenge. The technology is also being explored as a broader platform with potential applications in areas such as cardiology, hypertension and chronic pain management. However, the platform remains investigational and has not yet been cleared for marketing in the United States. The newly completed GLP study therefore represents a regulatory-development milestone rather than evidence of established clinical effectiveness.
Advertisement
FDA Submission Represents Next Development Milestone
With the GLP study now completed, Autonomix Medical is preparing to use the resulting safety, performance and histopathology data in its planned FDA regulatory submission. The company believes completion of the study demonstrates increasing maturity of its technology and strengthens its position as it transitions toward clinical-stage execution. The next major milestones will depend on the contents of the regulatory package and the FDA’s review, including any additional information or testing that may be required. Autonomix is seeking to develop a technology platform capable of providing more precise access to peripheral nerves through a minimally invasive catheter-based approach. If successfully cleared and subsequently validated in clinical studies, the platform could potentially address multiple diseases involving the nervous system. For now, the key takeaway is that completion of the GLP study provides supporting preclinical evidence for the company’s regulatory strategy, while future FDA review and clinical data will determine the technology’s ultimate medical and commercial potential.
Source:Autonomix Medical, press release
